Thrombin-Activatable Fibrinolysis Inhibitor, Human

Native thrombin-activatable fibrinolysis inhibitor from human liver. Single chain glycoprotein synthesized in the liver. ctivated by the thrombin/thrombomodulin complex by proteolytic cleavage at Arg⁹². Circulates in plasma as a zymogen at a concentration of about 50 nM. Believed to play an important role in the interaction between procoagulant, anticoagulant, and fibrinolytic systems.

Native thrombin-activatable fibrinolysis inhibitor from human liver. Single chain glycoprotein synthesized in the liver. Circulates in plasma as a zymogen at a concentration of 50 nM. Activated by thrombin-thrombomodulin complex by proteolytic cleavage at Arg⁹². Believed to play an important role in interaction between the procoagulant, anticoagulant, and fibrinolytic systems.

Please refer to vial label for lot-specific concentration.

Toxicity: Standard Handling (A)

One unit is defined as the amount of enzyme that will hydrolyze 1 µM Hip-L-Arg per min at 25°C, pH 7.65.

In 150 mM NaCl, 20 mM HEPES, pH 7.4.

Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Following initial thaw, aliquot and freeze (-70°C).

Boffa, M.B., et al. 1999. Biochemistry 38, 6547.
Boffa, M.B., et al. 1998. J. Biol. Chem. 273, 2127.
Bajzar, L., et al. 1995. J. Biol. Chem. 270, 14477.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany